Thus, the Nrf2 agonist dimethyl fumarate improved hematological parameters and reduced plasma-free Hb in SCD mice (Krishnamoorthy et al., 2017), whereas other authors showed that Nrf2 activation through ablation of its negative regulator Keap1 did not modify hemolysis and stress erythropoiesis in SCD mice, although it increased plasma heme clearance (Keleku-Lukwete et al., 2015). This evidence concerns the gene KEAP1 and Schnyder corneal dystrophy.